Long-Term Effectiveness of Tenofovir Alafenamide Versus Entecavir in Treatment-Naive Chronic Hepatitis B: A Real-World Evidence from the Global Alliance for the Study of Hepatitis B Virus

BR rates were similar with ETV and TAF, while VR and CR were higher with TAF, although the difference was modest (<5% overall, 7%-9% in high HBV DNA or ALT groups). Antiviral selection between TAF vs ETV should be based mainly on cost, side effect profile, and patient preference.

Authors

Institutions

Publication Details

Journal
The American Journal of Gastroenterology
Published
2025-12-12
DOI
https://doi.org/10.14309/ajg.0000000000003881
Primary Topic
Hepatitis B Virus Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Long-Term Effectiveness of Tenofovir Alafenamide Versus Entecavir in Treatment-Naive Chronic Hepatitis B: A Real-World Evidence from the Global Alliance for the Study of Hepatitis B Virus

Pei‐Chien Tsai, Takashi Honda, Seng Gee Lim, Norio Itokawa et al.
The American Journal of Gastroenterology
Hepatitis B Virus Studies
article

Long-Term Effectiveness of Tenofovir Alafenamide Versus Entecavir in Treatment-Naive Chronic Hepatitis B: A Real-World Evidence from the Global Alliance for the Study of Hepatitis B Virus

Pei‐Chien Tsai, Takashi Honda, Seng Gee Lim, Norio Itokawa, Wan‐Long Chuang, Yasuhito Tanaka, Wenjing Ni, Chao Wu, Ramsey Cheung, Hidenori Toyoda, Adrian Carlos Gadano, Tomonori Senoh, Mindie H. Nguyen, Jie Li, Chia‐Yen Dai, Jee‐Fu Huang, Ritsuzo Kozuka, Ei Itobayashi, Fajuan Rui, Philip Vutien, Ming‐Lun Yeh, Sebastián Marciano, Chung‐Feng Huang, Haruki Uojima, S. Van Der Linden, Kazuhiro Takahashi, Ming‐Lung Yu, Toru Ishikawa, Takanori Ito, Akito Nozaki, Angela Chau, Tsunamasa Watanabe, Koichi Takaguchi, Manabu Morimoto, Masaru Enomoto, Hiroshi Abe, Joanne Kimiko Liu, Yixuan Zhu, Masanori Atsukawa, Huy N. Trinh, Kaori Inoue, Mayumi Maeda, Kunihiko Tsuji
article en

Abstract

BR rates were similar with ETV and TAF, while VR and CR were higher with TAF, although the difference was modest (<5% overall, 7%-9% in high HBV DNA or ALT groups). Antiviral selection between TAF vs ETV should be based mainly on cost, side effect profile, and patient preference.

The American Journal of Gastroenterology
National Sun Yat-sen University (TW), Kaohsiung Medical University (TW), St. Marianna University School of Medicine (JP), National University of Singapore (SG), Saga University (JP), University of Washington (US), VA Palo Alto Health Care System (US), Cornell University (US), Yokohama City University Medical Center (JP), Hospital Italiano de Buenos Aires (AR), Kaohsiung Medical University Chung-Ho Memorial Hospital (TW), Kanagawa Prefectural Hospital Organization (JP), Nagoya City University (JP), National Center for Global Health and Medicine (JP), Saiseikai Niigata Daini Hospital (JP), Nanjing Drum Tower Hospital (CN), Ogaki Municipal Hospital (JP), Shinmatsudo Central General Hospital (JP), Stanford Medicine (US), Teine Keijinkai Hospital (JP), Asahi General Hospital (JP), National University Hospital (SG), Kagawa Prefectural Central Hospital (JP), Universidad Hospital Italiano (AR), Kanagawa Cancer Center, Osaka Metropolitan University (JP), Weill Cornell Medicine (US), Nagoya University (JP), Kitasato University (JP), Tokyo Metropolitan University (JP), Nippon Medical School (JP), Nanjing University (CN), Yokohama City University (JP), Kumamoto University (JP), Stanford University (US), The University of Osaka (JP)
Openalex Percentile: Top 48%
Hepatitis B Virus Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.